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ABSTRACT
Current combination therapies elicit high response rates in B cell malignancies, often using CD20 
antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive 
disease. Therefore, novel CD20 antibodies combining multiple effector mechanisms were generated. To 
study whether neutrophil-mediated destruction of B cell malignancies can be added to the arsenal of 
effector mechanisms, we chimerized a panel of five previously described murine CD20 antibodies to the 
human IgG1, IgA1 and IgA2 isotype. Of this panel, we assessed in vitro antibody-dependent cell-mediated 
cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and direct cell death induction capacity 
and studied the efficacy in two different in vivo mouse models. IgA antibodies outperformed IgG1 
antibodies in neutrophil-mediated killing in vitro, both against CD20-expressing cell lines and primary 
patient material. In these assays, we observed loss of CD19 with both IgA and IgG antibodies. Therefore, 
we established a novel method to improve the assessment of B-cell depletion by CD20 antibodies by 
including CD24 as a stable cell marker. Subsequently, we demonstrated that only IgA antibodies were able 
to reduce B cell numbers in this context. Additionally, IgA antibodies showed efficacy in both an 
intraperitoneal tumor model with EL4 cells expressing huCD20 and in an adoptive transfer model with 
huCD20-expressing B cells. Taken together, we show that IgA, like IgG, can induce ADCC and CDC, but 
additionally triggers neutrophils to kill (malignant) B cells. We conclude that antibodies of the IgA isotype 
offer an attractive repertoire of effector mechanisms for the treatment of CD20-expressing malignancies.
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Introduction
Three CD20 antibodies are clinically approved for the treat-
ment of patients with CD20-expressing Non-Hodgkin lym-
phomas and chronic lymphocytic leukemia. Rituximab, the 
first approved antibody to target CD20, functions via antibody- 
dependent cell-mediated cytotoxicity (ADCC) and comple-
ment-dependent cytotoxicity (CDC), without inducing direct 
cell death (Type I antibody characteristics).1 Ofatumumab was 
developed as a second-generation CD20 antibody, selected to 
enhance complement activation and is, in contrast to rituxi-
mab, fully human. The most recently approved CD20 antibody, 
obinutuzumab, is a afucosylated, which enhances ADCC. 
Furthermore, obinutuzumab differs from its predecessors by 
the ability to induce direct apoptosis, but it induces CDC to 
a lesser extend (type II antibody characteristics).2
Currently, standard treatment for the most prevalent lym-
phoma and leukemia includes CD20 antibodies. For diffuse 
large B cell lymphoma (DLBCL), first-line therapy encom-
passes R-CHOP (rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone). Although response rates are high, 
patients who initially respond often become resistant to ther-
apy. For these groups, outcome is particularly poor. Efforts to 
improve R-CHOP, such as intensifying antibody dose, che-
motherapeutics, or substituting rituximab for obinutuzumab 
have failed to show significant improvements in patient 
outcomes.3–5
For chronic lymphocytic leukemia (CLL), modifications of 
the treatment regimen are showing benefit. By substituting 
obinutuzumab for rituximab/ofatumumab, addition of 
Bruton’s Tyrosine kinase (BTK) inhibitors or the Bcl-2 inhibi-
tor venetoclax, significant progress is being made. 
Nevertheless, patients still relapse or progress frequently, and 
resistance to antibody therapy often occurs.6 Therefore, CD20 
antibodies eliciting different modes of action are urgently 
required.
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We previously described a novel panel of murine CD20 
antibodies with distinct variable regions.7 These antibodies all 
display Type I characteristics, and some induced more potent 
complement activation as mouse IgG2c antibodies than ritux-
imab or 7D8, a murine antibody with similar characteristics as 
ofatumumab. Upon chimerization of a subpanel of these CD20 
antibodies to human IgG1, one antibody gained the ability to 
perform both type I and type II properties.
The aim of our study was to enhance the potential of these 
antibodies to stimulate polymorphonuclear granulocytes 
(PMN). Therefore, we chose to chimerize them to the human 
IgA isotype, since this isotype was previously shown to elicit 
superior killing of tumor cells via PMN.8,9 Here, we compared 
the effector mechanisms of five novel antibodies as IgG1, IgA1 
and IgA2(m1) in vitro and assessed their efficacy in vivo.
Results
Antibody binding and glycoprofile
We compared the effector mechanisms of five CD20 antibodies 
as IgG1, IgA1 and IgA2(m1). The chimerized antibodies were 
named UMAB, with each number referring to the original 
murine antibody names described previously.7 First, antibody 
binding to CD20-expressing Ramos cells was evaluated by 
flow-cytometric analysis. All antibodies showed similar bind-
ing patterns between the IgG1, IgA1 or IgA2 isotypes of the 
different variable regions (Figure 1). In addition, binding was 
similar between the variable regions when compared between 
each isotype (Supplementary Figure 1).
Because glycosylation is an important therapeutic antibody 
feature, the glycoprofiles of our antibodies were analyzed by 
a mass-spectrometry-based approach. As expected, 
N-glycosylation of IgG1 antibodies was homogenous between 
antibodies (Supplementary Figure 2a). For the IgA1 antibodies, 
multiple major and minor glycoforms could be detected 
(Supplementary Figure 2b). Dominant signals included 
a nonfucosylated diantennary species with a single 
α2,6-sialylated galactose, as well as its variants with an addi-
tional galactose or without the sialic acid. Minor signals 
included tri- and tetraantenary species, α2,3-linked sialylation, 
fucosylation, as well as some high-mannose species. In general, 
the relative glycosylation was highly similar between the dif-
ferent IgA1 CD20 antibodies. All tested IgA2 antibodies shared 
the most prevalent glycoform with IgG1, a complex fucosylated 
diantennary glycan lacking galactose. Next to this, species with 
galactosylation and sialylation (both α2,3- and α2,6-linked) 
could be detected, differing somewhat in relative intensity 
depending on the antibody (Supplementary Figure 2c). 
Altogether, glycan analysis indicated the glycosylation to be 
consistent across antibodies of the same isotype (either IgG1, 
IgA1 or IgA2), but different between the isotypes.
Next, we studied the effector mechanisms of these antibo-
dies in ADCC, CDC and apoptosis assays.
IgA antibodies outperform IgG1 antibodies in 
PMN-mediated ADCC and B-cell depletion
We analyzed the capacity of the novel human IgG1, IgA1 and 
IgA2 CD20 antibodies to trigger ADCC against CD20- 
expressing tumor cells by human PMN. As previously observed 
with the murine variants of these antibodies, ADCC of the 
different antibodies was similar over a range of antibody con-
centrations between IgA1 (Figure 2a, left panel) and IgA2 
antibodies (Figure 2a, right panel).7 Interestingly, IgA2 anti-
bodies were able to lyse significantly more cells at the highest 
tested concentration compared to IgA1 for 4 of 5 tested anti-
bodies (Figure 2b). All IgG1 antibodies facilitated poor lysis by 
granulocytes in comparison to IgA antibodies (Figure 2b), as 
observed for other CD20 antibodies.1,1110
Next, we evaluated the ability of these antibodies to perform 
ADCC against isolated B cells with PMN as effector cells. In an 
autologous setting with B cells from a healthy donor, IgA2 
antibodies killed B cells more efficiently in comparison to 
IgG1, shown for two different donors (Figure 2c). Finally, 
ADCC assays on isolated primary B-CLL cells from a CLL 
patient were performed, with granulocytes from two different 
healthy donors as effector cells. Also here, IgG1 antibodies 
recruited PMN less efficiently as compared to IgA2 antibodies, 
although higher lysis was achieved for IgG1 antibodies than in 
the previous assays with healthy B cells (Figure 2d).
CD24 as an additional marker improves reliability of 
FACS-based B-cell depletion assays
In flow-cytometric autologous B-cell depletion assays with 
whole leukocytes, we initially gated on CD19+ cells to track 
B cells. Here, loss of CD19 in a concentration-dependent 
manner was observed, excluding cells from gating, thus letting 
us initially believe B cell reduction occurred for all antibodies 
in a similar fashion (Figure 3a). However, when CD24 was used 
as a secondary marker for B cells (gating strategy shown in 
Supplementary Figure 3), it became apparent that cells only 
lost CD19 (Figure 3b,c), but remained stable in CD24 staining, 
and were not killed, based on forward scatter (FSC)/side scatter 
Figure 1. CD20 antibodies bind similarly to CD20. Antibody-binding to Ramos 
cells analyzed by flow cytometry. Graphs show binding for IgG1, IgA1 and IgA2 for 
each different variable region antibody at several antibody concentrations. One 
representative graph is shown for at least n = 3 independent experiments.
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(SSC) values (Figure 3d). When gating on the CD24 + B cells, it 
became clear that IgG antibodies did not reduce B cell num-
bers, while IgA antibodies were able to significantly decrease 
B cell numbers (Figure 3e).
Apoptosis induction
Previously we have shown that after chimerization of 
UMAB001 to human IgG1, the antibody acquired the ability 
to induce homotypic aggregation and apoptosis, while retain-
ing type I antibody characteristics.7 Here, we evaluated the 
ability of the whole panel of chimerized antibodies as IgG1, 
IgA1 and IgA2 to induce apoptosis and lysosomal cell death. 
Interestingly, only IgG1 UMAB001 showed a significant 
amount of lysosomal cell death induction, while IgA variants 
with the same variable region induced a significantly lower 
amount of lysosomal cell death, as was assessed by lysotracker 
staining (Figure 4a). In addition, we also observed loss of 
mitochondrial membrane potential, indicative for apoptosis 
(Figure 4b). Obinutuzumab induced more direct cell death in 
comparison to IgG1 UMAB001.
CD20 antibodies of the IgA isotype activate the 
complement system via the classical pathway
Next, complement activation by these CD20 antibodies was 
investigated against Ramos cells. As expected, IgG antibodies 
efficiently performed cell lysis within 15 minutes incubation 
with human serum, while no to low amounts of lysis could be 
observed by IgA antibodies (Figure 5a). However, when the 
incubation time was increased, lysis mediated by IgA 
Figure 2. ADCC by a panel of CD20 antibodies of the IgA1, IgA2 and IgG1 isotype. 
(a) PMN-mediated ADCC against Ramos cells by IgA CD20 antibodies at several 
antibody concentrations. After 4 h at 37°C,51-Cr-release was measured to assess 
specific lysis. PMN were added to tumor cells at an ET ratio of 40:1. One 
representative graph is shown for at least n = 3 independent experiments. (b) 
Maximal lysis achieved by antibodies in A. Asterisks indicate statistically signifi-
cant differences between IgG1 and IgA antibodies. Capped lines with asterisks 
indicate a statistically significant difference between IgA1 and IgA2 antibodies. (c) 
ADCC assays against healthy B cells with autologous PMN as effector cells. 
Antibodies were added to tumor cells at 5 µg/ml. PMN were added to tumor 
cells at an ET ratio of 40:1. After 4 h at 37°C,51-Cr-release was measured to assess 
specific lysis. Results of two different donors are shown (left and right panel). 
Asterisks indicate a significant difference to the no Ab control. (d) B-CLL ADCC 
assays with allogenic PMN as effector cells. Results of two different PMN donors 
are shown (left and right panel). After 4 h at 37°C,51-Cr-release was measured to 
assess specific lysis. Antibodies were added to tumor cells at 4 µg/ml. PMN were 
added at an E:T ratio of 40:1. Asterisks indicate statistically significant differences 
to the no Ab control.
Figure 3. CD24 is a stable marker for B cell depletion and indicates B-cell 
depletion more closely than CD19. WBLs were incubated for 4 h at 37°C in the 
presence of CD20 antibodies. The level of B-cell depletion was analyzed by flow 
cytometry. (a) Apparent loss of B cells mediated by IgA1, IgA2 and IgG1 CD20 
antibodies. (b) Effect of increasing antibody concentration (IgA1 UMAB001) on 
CD19 levels. (c) Quantification of CD19 expression at several antibody concentra-
tions, gated on CD24 + B cells (d) Quantification of CD24 expression on initially 
CD19 positive B cells. (e) Quantification of remaining B cells after whole blood 
leukocyte-mediated B cell depletion assay with CD20 antibodies gating on 
CD24 + B cells. One representative graph is shown for at least n = 3 independent 
experiments. Asterisks indicate statistically significant differences compared to 
the no Ab control.
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antibodies substantially increased for all tested antibodies. 
IgG1 antibodies reached maximal lysis after 15 minutes, 
while IgA antibodies reached maximal lysis after 4 h. At the 
highest tested antibody concentration, IgG antibodies induced 
significantly more lysis in comparison to IgA antibodies with 
the same variable regions. IgA1 and IgA2 antibodies did not 
differ significantly in CDC induction at this concentration 
(Figure 5b). At lower concentrations, IgA2 antibodies induced 
more lysis in comparison to IgA1 antibodies (Supplementary 
Figure 4a). Since IgA antibodies do not contain a C1q binding 
site, we assessed which complement pathway is responsible for 
complement-mediated lysis by IgA antibodies. Through the 
use of C1q-depleted serum, the contribution of the classical 
pathway was studied. Interestingly, lack of C1q completely 
inhibited CDC by IgA and IgG1 antibodies. Supplementing 
recombinant C1q to the depleted serum restored CDC for both 
IgA and IgG antibodies, indicating that both isotypes require 
the classical complement pathway for CDC (Figure 5c).
As expected, inhibition of all complement activity by ethy-
lenediaminetetraacetic acid (EDTA) or heat inactivation of 
serum showed that both IgA and IgG require a functional 
complement system to achieve lysis with serum 
(Supplementary Figure 4b). All tested isotypes mediate lysis 
through the terminal complement pathway, as pretreatment of 
serum with the C5 inhibitor eculizumab completely inhibited 
CDC (Supplementary Figure 4b). By inhibiting all except the 
alternative pathway through treatment of serum with 
MgEGTA, we showed that the alternative pathway does not 
play a role in IgA and IgG-mediated complement activation 
(Supplementary Figure 4b).
Previously, it was described that binding of CD20 by type 
I antibodies lacking a C1q binding site can indirectly initiate 
complement activation through formation of a lipid raft on the 
membrane containing the B cell receptor (BCR) of the IgM or 
IgG subclass. Since these BCRs do contain a C1q binding site, it 
was suggested that this clustering can form a platform with 
enough avidity for C1q binding, and, therefore, complement 
activation.11 To assess whether the BCR was important for IgA- 
mediated complement activation, the BCR was knocked-out in 
Ramos cells via CRISPR/Cas9 to further investigate this. As 
described previously, knock-out of the BCR did not significantly 
influence CDC by non-C1q binding antibodies.12 This also held 
true for all tested IgA antibodies (Supplementary Figure 4c).
IgA antibodies show tumor kill and B cell depletion in vivo
To compare the efficacy of these antibodies in vivo, C57BL/6 
mice either expressing the human FcαR (CD89) or not were 
intraperitoneally (IP) injected with EL4 cells expressing human 
CD20, and, after 24 hours, 100 µg of antibodies was injected at 
the same site. After 24 hours of therapy, peritoneal lavage was 
performed to gather the remaining EL4 cells. Over this short 
period, all injected antibodies reduced tumor cells to a similar 
extend (Figure 6a) in the model.
Figure 4. Apoptosis induction by CD20 antibodies. Apoptosis induction on Ramos 
cells by CD20 antibodies at 10 µg/ml. After 6 h of incubation time at 37°C, cells 
were stained with (a) lysotracker red or (b) DioC6 and analyzed by flow cytometry. 
Results are shown of a single experiment.
Figure 5. IgA antibodies activate the complement system via the classical path-
way. (a) FACS-based CDC assay against Ramos cells by isotype variants of CD20 
UMAB002 antibodies at 10 µg/ml at indicated timepoints at 37°C. (b) FACS-based 
CDC assay against Ramos cells by IgA CD20 antibodies at 10 µg/ml for 4 h at 37°C. 
Asterisks indicate a significant difference with IgG antibodies with the same 
variable region. (c) CDC assay against Ramos cells by IgA CD20 antibodies at 
10 µg/ml in presence or absence of C1q for 4 h at 37°C. One representative graph 
is shown for at least n = 3 independent experiments.
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In a second in vivo model, B cell depletion by UMAB010 
IgA1, IgA2 and IgG1 antibodies was investigated. Here, CD89 
transgenic (Tg) mice were injected with a mix of CellTrace 
Violet (CTV)-labeled splenocytes from huCD20 Tg and 
huCD20 NTg mice. Mice were injected with 37.5 µg of IgG1 
or 150 µg of IgA antibodies. In this model, all tested CD20 
antibodies significantly decreased the number of CD20- 
expressing B cells. Taken together, these results signify the 
use of IgA as an antibody isotype for CD20-expressing B cell 
malignancies.
Discussion
Here, we have shown that conversion of human IgG1 antibo-
dies against CD20 to the human IgA isotype enhances neutro-
phil-mediated killing of B cells and elicits CDC. Additionally, 
CD20 antibodies of the IgA isotype showed efficacy in two 
different mouse models in vivo. These data support the concept 
that monoclonal antibodies of the IgA isotype could be 
a treatment option for CD20-expressing lymphomas.
However, the clinical application of IgA is hindered by 
several factors. First, IgA1 and IgA2 antibodies contain more 
N-glycosylation sites compared to the IgG1 isotype. This com-
plexity is a well-recognized issue for protein-based therapeutics 
because it contributes to drug heterogeneity. Furthermore, the 
high amount of N-glycosylation negatively influences in vivo 
half-life in mice through interaction with the asialoglycopro-
tein receptor in the liver.13,14 Therefore, half-life of IgA is 
relatively short in comparison to IgG1. Although the half-life 
of IgA in humans is 6 d, in mice a half-life of approximately 1 
d is observed.
Heterogeneity in protein glycosylation influences the 
function, pharmacokinetics and safety of biological thera-
peutics, and it is therefore a critical attribute.15 Because 
IgA1 contains 2 N-glycosylation sites per heavy chain, the 
number of different glycans found was more diverse in 
comparison to IgG1, although heterogeneity remained lim-
ited between antibodies. IgA2 antibodies incorporate five 
distinct N-glycosylation sites on each heavy chain, but has 
the advantage over IgA1 that it is not O-glycosylated and is 
not associated with development of IgA nephropathy. The 
two different antibodies of the IgA2 isotype analyzed in this 
study differed in their N-glycosylation pattern. However, 
more antibodies, stable cell line development, and testing 
of different batches is required to get a clearer image 
regarding this important drug property.
To investigate the B-cell depleting capacity of IgA CD20 
antibodies, we used both51-Cr-release assays and a flow cyto-
metric approach. Using the latter method, we were able to 
determine B-cell loss in an autologous setting with whole 
blood leukocytes. At first, we noticed a reduction of CD19 
levels after addition of antibody to these cells. This observa-
tion is reminiscent of the shaving effect described for CD20, 
attributed to Fc receptor-mediated trogocytosis after CD20 
antibody exposure to target cells.51-Cr-release assays and 
a flow cytometric approach. Using the latter method, we 
were able to determine B-cell loss in an autologous setting 
with whole blood leukocytes. At first, we noticed a reduction 
of CD19 levels after addition of antibody to these cells. This 
observation is reminiscent of the shaving effect described for 
CD20, attributed to Fc receptor-mediated trogocytosis after 
CD20 antibody exposure to target cells.16 This led us to 
believe that CD19 might also be concomitantly removed 
from B cells as CD19 resides in the same protein-membrane 
domains at the cell surface.17,18 Considering this, we included 
CD24 as an additional B cell marker in our analysis, which is, 
to our knowledge, not associated with the aforementioned 
CD20 protein-membrane domain and was not affected by 
CD20 antibody treatment in the presence of leukocytes. In 
agreement with published data concerning rituximab- 
mediated CD19 loss, we observed that both IgG and IgA 
CD20 antibodies dramatically reduced CD19.10 These experi-
ments demonstrated that in this context, only CD20 antibo-
dies of the IgA isotype were capable of reducing B cell 
numbers. Macrophages, and in particular neutrophils, have 
recently been indicated to exert ADCC by a trogocytosis- 
based mechanism called trogoptosis.19,20 This cell-death 
Figure 6. In vivo efficacy of CD20 antibodies. (a) EL4-CD20 intraperitoneal model. 
CD89 Tg and NTg C57bl/6 j mice were injected IP with EL4-CD20 cells and 16 
h later were treated with 100 µg of CD20 antibodies or phosphate-buffered saline 
(PBS). After 24 h, the number of tumor cells in the peritoneal wash was deter-
mined by flow cytometry via TrueCount tubes (4–12 mice per group, data of two 
pooled independent experiments are shown). Asterisks indicate a statistically 
significant difference compared to the PBS-treated group. (b) CD89 Tg and NTg 
C57bl/6 j mice were i.v. injected with huCD20+ and CD20- murine splenocytes 
labeled with a with either a high or low concentration of CellTrace Violet. After 
24 h, mice were injected intravenously with 37.5 µg of IgG1 or 150 µg of IgA 
antibodies to correct for differences in half-life. After 16 h, spleens were isolated 
and the ratio of huCD20+ and huCD20- murine B220+ splenocytes was deter-
mined by flow cytometric analysis. Asterisks indicate statistically significant differ-
ences compared to the PBS-treated group.
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inducing mechanism by neutrophils is profoundly more effec-
tive when mediated by the IgA isotype, and can be attributed 
to a strong triggering of CD89 present on neutrophils.8,21 
Strikingly, we did not observe IgG-mediated B cell reduction 
with whole blood leukocytes as effector cells, although CD20 
IgG1 antibodies have shown clear clinical benefit. One possi-
ble explanation could be that IgG-mediated trogocytosis of 
CD20 by the vast numbers of neutrophils in blood does not 
reflect the tumor microenvironment in patients. Nevertheless, 
CD19 is still often used as a marker for B cell depletion. Based 
on our experience and results, we strongly encourage reeva-
luation of the use of CD19 as the only biomarker for assess-
ment of CD20 therapeutics.
When we tested complement activation of the novel 
chimerized antibodies, the same order of efficacy was 
observed as with mouse antibodies. As shown before, 
UMAB001, UMAB007 and UMAB009 elicited a high degree 
of complement activation while UMAB002 showed this to 
a lower extent.7 The same order was also observed between 
the IgA antibodies, indicating that the variable region 
strongly dictates the ability to perform CDC. Interestingly, 
although both the IgA1 and IgA2 Fc tail lack a C1q binding 
site, all IgA antibodies could perform CDC against CD20- 
expressing cell lines. Previously, it was reported that CD20 
antibodies lacking a C1q binding site could activate the 
classical complement pathway, through indirect clustering 
of the BCR.11 Although it was shown that the BCR could 
evoke this, other molecules present within the CD20 lipid 
raft are likely to show this as well, since the same effects 
could be obtained after knock-out of this receptor.12 We 
hypothesize that other molecules present within the CD20 
lipid raft containing a C1q binding site also are able to bind 
C1q after clustering. Likely candidate molecules able to 
bind C1q on B cells are CD21, CD35, CD93 and the 
gC1qR. Nevertheless, it is questionable how relevant IgA- 
mediated CDC will be in patients, since even strong CDC- 
inducing antibodies such as ofatumumab do not show 
a clear clinical benefit over rituximab or obinutuzumab 
for CLL or DLBCL patients.22,23
Although this panel of antibodies showed both differ-
ences between isotypes and between variable regions 
in vitro, the short IP model did not show substantial differ-
ences in tumor cell killing between the antibody groups. 
This model showed a rather large variation within 
a treatment group, perhaps because of the site of injection. 
The intraperitoneal cavity is often used as an injection site 
for in vivo tumor models, but cells can adhere easily in this 
site, which can influence the recovery after peritoneal 
lavage. Therefore, the model might not be ideal for com-
parison of a panel of antibodies. This variation is not 
inherent to the therapeutic antibody, since, in a second 
adoptive transfer model, inter-treatment variation could 
be reduced. To improve the short IP model for future 
experiments, we propose to include a reference population 
of cells, as was done for the adoptive transfer model. That 
way, a ratio, instead of an absolute number of cells, can be 
determined.
To conclude, we showed that chimerization of a panel of 
five novel antibodies to the IgA isotype showed an 
interesting repertoire of effector mechanisms: strong activa-
tion of PMN together with low, but still significant, com-
plement activation. In the future, it will be especially 
important to evaluate whether this combination of effector 
mechanisms can be beneficial in the refractory/relapsed 
setting for CD20-expressing malignancies.
Materials and methods
Cell lines
All cell lines were cultured in RPMI culture medium supple-
mented with HEPES, glutamax, 10% fetal calf serum, 100 U/ 
mL penicillin-streptomycin (Gibco, Life Technologies) at 37°C 
in a humidified incubator containing 5% CO2. HEK293F cells 
were cultured in FreeStyle 293 expression medium at 37°C in 
a humidified incubator with orbital shaker platform containing 
8% CO2.
Antibodies
Antibodies were produced and purified as previously 
described.13 Briefly, variable heavy chain sequences coding 
for IgA1, IgA2(m1) or IgG1 and the variable kappa light 
chain sequence were separately cloned into a Lonza expression 
vector (pEE14.4). Monomeric antibodies were produced by 
transient transfection of HEK293F cells with vectors coding 
for the heavy chain, light chain and pAdvantage (accession 
number U47294; Promega), using 293 Fectin transfection 
reagent according to the manufacturer’s instructions. IgG1 
antibodies were purified using protein A columns (Hi-trap 
protein A) coupled to an ÄKTAprime plus chromatography 
system (GE Lifesciences). Bound antibody was eluted with 0.1 
M sodium acetate pH 2.5 and neutralized with 1 M TRIS-HCl 
pH 8.8. The eluate was dialyzed against phosphate-buffered 
saline (PBS). IgA antibodies were purified using kappa light 
chain affinity chromatography columns (Hi-trap kappaSelect, 
GE healthcare) and eluted with 0.1 M glycine buffer pH 2.5. 
The eluate was applied on a SEC column ran with PBS as 
mobile phase. The fractions containing monomeric IgA were 
collected and concentrated with a 100 kDa spin column 
(Vivaspin 20, GE Healthcare). All antibodies were filtered 
over 0.22 µm filters.
Binding assays
1x105 cells were plated out in 96-well plates, washed and incu-
bated with antibody at several concentrations for 45 minutes on 
ice. Next, cells were washed and stained by a secondary phycoer-
ythrin-conjugated anti-IgA or IgG antibody (Southern Biotech 
#2042-09, #2052-09). Finally, cells were washed and resuspended 
in PBS. The amount of bound antibody to the cells was deter-
mined by flow cytometry (BD FacsCanto II). Results were dis-
played as % maximal binding (MFI/MFImax)x 100%.
Mass spectrometric glycan analysis
Chemicals and reagents used for mass spectrometry (MS) were 
as follows: high purity water (MQ) was generated using 
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a Q-Gard 2 system (Millipore, Amsterdam, Netherlands), 
maintained at ≥18 MΩ. Ethanol, trifluoroacetic acid (TFA), 
sodium dodecyl sulfate (SDS), Na2HPO4 x 2H2O, KH2PO4 and 
NaCl were purchased from Merck (Darmstadt, Germany). 
Nonidet P-40 substitute (NP-40), 1-hydroxybenzotriazole 
(HOBt), super-DHB and 50% NaOH originated from Sigma- 
Aldrich (Steinheim, Germany), while 1-ethyl-3-(3-dimethyla-
minopropyl)carbodiimide (EDC) hydrochloride was bought 
from Fluorochem (Hadfield, U.K.), peptide-N-glycosidase 
F (PNGase F) from Roche Diagnostics (Mannheim, 
Germany), and HPLC SupraGradient acetonitrile (ACN) 
from Biosolve (Valkenswaard, Netherlands).
Antibody glycans were prepared for mass spectrometric 
analysis by enzymatic release and chemical derivatization as 
reported previously.24,25 Briefly, 20 µL 2% SDS was added to 
10 µL antibody sample, followed by 10 min incubation at 60° 
C. After letting the samples cool to room temperature, 20 µL 
release mix was added containing 2% NP-40 and 2.5 mU 
PNGase F in 2.5x PBS (14.25 g/L Na2HPO4 x 2H2O, 1.25 g/L 
KH2PO4 and 21.25 g/L NaCl), followed by overnight incuba-
tion at 37°C. Next, 5 µL of the release mixtures was deriva-
tized by adding 35 µL 0.25 M EDC + 0.25 M HOBt in ethanol 
and incubating for 1 h at 37°C, resulting in lactones for 
α2,3-linked sialic acids and ethyl esters for α2,6-linked sialic 
acids.24,25 40 µL ACN was subsequently added to prepare for 
glycan enrichment. The glycans were recovered from the 
reaction mixture by hydrophilic interaction liquid chromato-
graphy (HILIC) solid phase extraction (SPE), using cotton as 
stationary phase.26 For this, 200 µL pipette tips were packed 
with 200 µg cotton, washed three times with 100 µL MQ, and 
three times with 100 µL 85% ACN. Next, the glycans were 
loaded by pipetting the samples up and down 30 times, 
followed by three washes with 100 µL 85% ACN 1% TFA, 
another three washed with 100 µL 85% ACN, and eluted in 
10 µL MQ.
One microliter of the eluted samples was spotted on an 
MTP AnchorChip 600/384 TF target (Bruker Daltonics, 
Bremen, Germany), and mixed on-plate with 1 µL 5 mg/mL 
super-DHB 1 mM NaOH in 50% ACN. Matrix-assisted laser 
desorption/ionization (MALDI)-time-of-flight (TOF)-MS was 
carried out using reflectron positive ion mode of an 
UltraFlextreme system (Bruker Daltonics) controlled by 
flexControl 3.4 Build 135 (Bruker Daltonics). The instrument 
was calibrated before measurement using a peptide calibration 
standard (Bruker Daltonics). Laser power was set as high as 
possible to still allow baseline separation of isotopic peaks. 
Sample spectra were acquired by summing 10000 laser shots 
in a random walking pattern, at a frequency of 1000 Hz, and 
using a window from m/z 1000 to 5000 with suppression up 
to m/z 950.
Antibody-dependent cell-mediated cytotoxicity assays
ADCC assays were performed as described previously.27 In 
short, target cells were labeled with 3.7 MBq5Cr 
(PerkinElmer) per 1 × 106 cells in PBS for 2 hours. 
Afterward, cells were washed three times to remove excess 
chromium. Blood for ADCC assays was obtained from 
healthy donors at the UMC Utrecht (Medical ethical 
approval protocol 07−125/O). For leukocyte isolation, 
blood was incubated in water for 30 seconds to lyse ery-
throcytes. Afterward, 10x PBS was added to reach physio-
logical osmolality. Cells were washed and resuspended in 
medium corresponding to the original blood volume. For 
PMN and peripheral blood mononuclear cell (PBMC) iso-
lation, blood was added on top of a Ficoll (GE Healthcare)/ 
Histopaque 1119 (Sigma) layer and centrifuged for 20-
minutes at 1500 RPM. Afterward, PBMCs and PMNs 
were collected from the interphase between serum and 
Ficoll or in the Histopaque layer, respectively. For ADCC 
using primary human B cells as targets, magnetic activated 
cell sorting was performed to isolate healthy B cells (B-cell 
isolation kit II, Miltenyi) or malignant B cells (B-CLL iso-
lation kit, Miltenyi) from the PBMC fraction. Isolated 
malignant B cells were cryo-preserved and thawed immedi-
ately before use. The effector-to-target (E:T) ratios were 
100:1 for PBMCs and 40:1 for PMNs, unless stated other-
wise. Effector cells, antibodies and tumor cells were added 
to round-bottom microtiter plates (Corning Incorporated) 
and incubated for 4 hours at 37°C in a humidified incuba-
tor containing 5% CO2. For ADCC assays with healthy 
primary B cells as targets, autologous plasma was used for 
the incubation medium. Plates were centrifuged for 2-
minutes at 1500 RPM and 50 µL of the supernatant was 
transferred to Lumaplates (PerkinElmer). Radioactive scin-
tillation (in cpm) was quantified in a beta-gamma counter 
(PerkinElmer). Specific lysis was calculated using following 
the formula: ((experimental cpm – basal cpm)/(maximal 
cpm – basal cpm)) x 100, with maximal lysis determined 
by incubating labeled cells with 1.25% triton and minimal 
lysis in the absence of antibodies and effector cells.
B-cell depletion assays
For monitoring the level of B-cell depletion by CD20 antibo-
dies in an autologous setting, whole blood leukocytes (WBLs) 
from blood of healthy donors were separated from the ery-
throcyte bulk by Ficoll/Histopaque block gradient centrifuga-
tion as described for the ADCC assay above. This was followed 
by an ammonium buffer (155 mM NH4 Cl, 10 mM KHCO3, 
0.037 mg/mL Na2EDTA, pH 7.4) based erythrocyte lysis pro-
cedure. WBLs were then added to and mixed in 96-well 
V-bottom plates (0.2–0.4x106 cells per well) containing the 
desired antibodies in a total volume of 50 µL medium per 
well in a triplicate setup and incubated for 3–4 hours at 37°C. 
After this, WBLs were washed and stained for CD19-APC 
(Biolegend, clone HIB19, # 302212), CD11b-PE (BD, clone 
D12, # 347557), CD3-PerCp (BD, clone UCHT1, # 560835), 
CD56-AF488 (BD, clone B159, # 561905), CD14-V500 (BD, 
cloneM5E2, #561391), CD24-BV421 (Biolegend, clone ML5, 
#311122) and quantitatively analyzed by flow cytometry by 
measuring a fixed volume of cell suspension for each well 
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(FACScanto II HTS setup, BD biosciences). B cells were 
defined as CD3−/CD56−/CD14−/CD24+/CD19hi-lo cells.
CDC assays
105 lymphoma cells were added per well to 96-well microtiter 
plates and incubated for 30 minutes with antibodies at various 
concentrations at room temperature. Afterward, pooled 
human serum (from 8 different healthy donors), or C1q- 
depleted serum (Complement technologies) was added to 
a final concentration of 15% and incubated for 15 min, 1 h or 
4 h. When indicated, C1q was supplemented to 60 µg/mL, 
pooled serum was treated with 10 mM EDTA (Sigma 
Aldrich), 10 mM EGTA and 2 mM MgCl2 (Sigma Aldrich), 
40 µg/mL eculizumab or heat inactivated for 30 minutes at 56° 
C. Afterward, cells were washed and stained with 7-AAD (BD 
Pharmingen) for 15 minutes. 7-AAD uptake was quantified by 
flow cytometry (FACScanto II, BD biosciences).
Direct cell death induction assays
To analyze direct Fab-mediated cell death of lymphoma cells, 
1 × 105 target cells were incubated with CD20 antibodies (all at 
10 μg/ml) at 37°C and 5% CO2. To quantify lysosomal cell 
death or apoptosis, target cells were incubated with CD20 
antibodies at 10 µg/ml at 37°C and 5% CO2. After 5 hours of 
incubation, lysotracker red (Invitrogen) was added for 1 h at 
50 nM to determine lysosomal cell death or cells were treated 
after 6 h with 10 nM of DiOC6 (Thermo Fisher), and TO-PRO 
-3 (Thermo Fisher), following the manufacturer’s instructions. 
Afterward, cells were washed and analyzed by flow-cytometry 
(BD LSRFortessa).
In vivo experiments
Mice were maintained in the animal facility of the University of 
Utrecht. Experiments were conducted using both male and 
female C57Bl/6JRj mice (Janvier). Mice were housed in groups 
under a 12:12 light–dark cycle, with food and water available 
ad libitum. Mice were acclimatized for at least 1 week prior to 
the start of experiment. Sample sizes were calculated with 
power analysis at the time of the design of experiments.
All experiments were performed in accordance with 
international guidelines and approved by the national 
Central Authority for Scientific Procedures on Animals 
(CCD) and the local experimental animal welfare body 
(AVD115002016410).
Short IP model
In vivo evaluation was performed using the EL4-CD20 low 
tumor-burden model as previously described.29 C57BL/6 
mice were purchased from Janvier (Le Genest-Saint-Isle, 
France) or bred in our facilities. 4–12 mice/group were IP 
injected with 5 × 106 CellTraceViolet (1 µM, Invitrogen)- 
labeled EL4-CD20 cells. After 16 hours, mice were treated 
with 100 µg antibody or PBS (100 µL) injected IP. 
A peritoneal lavage with PBS containing 5 mmol/L EDTA 
was performed after 24 hours and the amount of remaining 
tumor cells was determined using TruCount tubes (BD). To 
compare the complete panel of antibodies, data were pooled 
from two separate in vivo experiments.
Adoptive transfer in vivo model
hCD20 transgenic mice have been described previously and 
were provided by the University of Southampton.29 Mice were 
backcrossed with hCD89 Tg on a C57BL/6 background in our 
facilities. Mice were injected subcutaneously with 20 µg PEG- 
G-CSF. After 4 d, we sacrificed a CD20 Tg and Non-Tg C57BL/ 
6 mouse and harvested splenocytes by mechanical dissociation 
of the spleen. Splenocytes were labeled with 0.5 or 5 µM of 
CellTrace Violet for 20 minutes, mixed in a 1:1 ratio and 
injected intravenously (i.v.) in CD89 Tg or CD89 NTg mice. 
After 24 hours, mice were i.v. injected with 250 µg of antibody. 
After 16 hours, mice were sacrificed and splenocytes were 
harvested and analyzed by flow cytometry. Injected B cells 
were identified based on CellTrace Violet+, B220+ 
(Biolegend, clone RA3-6B2, #103222) labeling.
CRISPR/Cas9 of IGMH
Knock-out (KO) of the BCR on Ramos cells was performed by 
CRISPR/Cas9 guided targeting of the Immunoglobulin Heavy 
Constant Mu gene (IGMH). In short, a single guide RNA 
(sgRNA, TCCGACGGGGAATTCTCAC) targeting IGMH 
was introduced in the lentiviral pSicoR-CRISPR-PuroR vector 
and target cells were subsequently transduced with lentiviral 
particles and selected using puromycin treatment (1 µg/ml).30 
Flow cytometric analysis after 14 d demonstrated loss of mem-
branous IgM expression from the majority of cells. To obtain 
a population of pure BCR KO cells, cells that were left 
unstained by an anti-IgM monoclonal antibody (BD, Clone 
G20-127, #562618) were sorted by FACS (FACSAria II, BD).
Data processing and statistical analysis
Statistical analyses were performed in GraphPad prism 8.3 
software (GraphPad). Data are represented as mean ± SD. 
For comparing mean values of two groups, unpaired two- 
tailed Student’s T-tests were performed. For multiple compar-
isons, two-tailed one-way ANOVA was performed with 
Tukey’s range test. Dose–response curves for ADCC experi-
ments were calculated via non-linear regression. Asterisks were 
used to indicate statistical significance (p < .05).
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